JP2006521409A5 - - Google Patents

Download PDF

Info

Publication number
JP2006521409A5
JP2006521409A5 JP2006509466A JP2006509466A JP2006521409A5 JP 2006521409 A5 JP2006521409 A5 JP 2006521409A5 JP 2006509466 A JP2006509466 A JP 2006509466A JP 2006509466 A JP2006509466 A JP 2006509466A JP 2006521409 A5 JP2006521409 A5 JP 2006521409A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
group
unsubstituted
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006509466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521409A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/009667 external-priority patent/WO2004087075A2/en
Publication of JP2006521409A publication Critical patent/JP2006521409A/ja
Publication of JP2006521409A5 publication Critical patent/JP2006521409A5/ja
Ceased legal-status Critical Current

Links

JP2006509466A 2003-03-28 2004-03-29 癌を処置するための組成物および方法 Ceased JP2006521409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45884503P 2003-03-28 2003-03-28
US46528103P 2003-04-21 2003-04-21
PCT/US2004/009667 WO2004087075A2 (en) 2003-03-28 2004-03-29 Compositions and methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012014178A Division JP5572644B2 (ja) 2003-03-28 2012-01-26 癌を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2006521409A JP2006521409A (ja) 2006-09-21
JP2006521409A5 true JP2006521409A5 (https=) 2007-05-24

Family

ID=33135116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006509466A Ceased JP2006521409A (ja) 2003-03-28 2004-03-29 癌を処置するための組成物および方法
JP2012014178A Expired - Fee Related JP5572644B2 (ja) 2003-03-28 2012-01-26 癌を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012014178A Expired - Fee Related JP5572644B2 (ja) 2003-03-28 2012-01-26 癌を処置するための組成物および方法

Country Status (14)

Country Link
US (2) US7550496B2 (https=)
EP (2) EP2671581B8 (https=)
JP (2) JP2006521409A (https=)
KR (2) KR101198526B1 (https=)
CN (2) CN1791403A (https=)
AU (1) AU2004226338C1 (https=)
CA (1) CA2520000C (https=)
ES (1) ES2759176T3 (https=)
IL (1) IL170970A (https=)
MX (1) MXPA05010407A (https=)
NO (1) NO336266B1 (https=)
NZ (1) NZ543223A (https=)
WO (1) WO2004087075A2 (https=)
ZA (1) ZA200507752B (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
DE50305909D1 (de) * 2003-10-13 2007-01-18 Salama Zoser B Pharmazeutische Zusammensetzung umfassend Oxoplatin und dessen Salze
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
GB0421296D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
JP2006282653A (ja) * 2005-03-10 2006-10-19 Kyoto Univ 標的部位で選択的に活性化される新規化合物およびその利用
CN102746336B (zh) * 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
EP2136626A4 (en) 2007-03-19 2011-02-23 Oregon State Mannich base n-oxide drugs
WO2008151253A1 (en) * 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
WO2009018163A1 (en) * 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
WO2009033165A1 (en) * 2007-09-06 2009-03-12 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of bis-alkylating agents
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
JP5765634B2 (ja) 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2010073126A2 (en) * 2008-12-22 2010-07-01 The Governors Of The University Of Alberta Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof
CN101538256B (zh) * 2009-04-28 2014-05-21 沈阳药科大学 3，4-二芳基呋喃-2，5-二酮类衍生物与3，4-二芳基-1h-吡咯-2，5-二酮类衍生物及其用途
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2012009288A2 (en) 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
CA2820245A1 (en) * 2010-12-06 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
US9402820B2 (en) 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
CN102260273B (zh) * 2011-05-13 2015-04-22 兰州大学 脱氧鬼臼与5-氟尿嘧啶的拼合物及其制备与用途
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2643403T3 (es) 2011-12-28 2017-11-22 Global Blood Therapeutics, Inc. Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
BR112014017833A2 (pt) 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
US9655975B2 (en) 2012-02-13 2017-05-23 University Of Tsukuba Prodrug using nitroimidazole
CN104204035B (zh) 2012-03-30 2017-05-24 宇部兴产株式会社 具有封端基团的聚轮烷的制造方法
WO2014058974A1 (en) * 2012-10-10 2014-04-17 Emory University Methods of managing inflammation using glycolysis pathway inhibitors
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US10037382B2 (en) 2012-10-29 2018-07-31 Kyocera Corporation Surface acoustic wave sensor
CN107412163A (zh) 2012-12-03 2017-12-01 梅里马克制药公司 用于治疗her2‑阳性癌症的组合疗法
EP2777694A1 (en) 2013-03-14 2014-09-17 Brij P. Giri Hypoxia-Targeted Polymeric Micelles for Cancer Therapy and Imaging
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014150261A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulaton of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
MX379235B (es) 2013-03-15 2025-03-11 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2014181314A1 (en) 2013-05-10 2014-11-13 Department Of Biotechnology Placental like alkaline phosphatase (plap) promoter mediated cell targeting
US20160158253A1 (en) 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
CN104434876B (zh) * 2013-09-13 2018-04-27 布里吉·P·吉里 用于癌症疗法及成像的缺氧-标靶聚合微胞
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
BR112017019287B1 (pt) 2015-03-10 2024-01-02 Obi Pharma, Inc Composto, e composição farmaceuticamente aceitável
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US10829437B2 (en) 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CN105250325A (zh) * 2015-10-28 2016-01-20 淄博齐鼎立专利信息咨询有限公司 Demissine在制备治疗肾癌药物中的应用
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CN106554375B (zh) * 2016-06-08 2019-10-18 浙江海正药业股份有限公司 一种蒽环类化合物、其制备方法及其用途
US20210369746A1 (en) 2016-08-01 2021-12-02 Molecular Templates, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CN106977501A (zh) * 2017-03-20 2017-07-25 华东师范大学 一种基于2‑硝基咪唑‑1‑烷基醇的低氧激活前药
CN107417672A (zh) * 2017-04-12 2017-12-01 华东师范大学 一种基于2,2‑二甲基‑3‑（2‑硝基咪唑基）丙酸的低氧激活前药
WO2019055786A1 (en) * 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
KR102747229B1 (ko) 2021-08-10 2024-12-31 경북대학교 산학협력단 두경부암의 예후 예측을 위한 암 관련 섬유아세포의 바이오마커
JP2024531479A (ja) 2021-08-27 2024-08-29 アセンタウィッツ ファーマシューティカルズ リミテッド 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN113968867A (zh) * 2021-11-10 2022-01-25 聊城大学 一种喜树碱类前药及其用途
US20240424011A1 (en) * 2021-12-21 2024-12-26 University Of Tsukuba Combination therapy of hypoxia-responsive prodrug of an anticancer drug and radiotherapy, and novel hypoxia-responsive prodrug
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
CN116675620B (zh) 2022-02-22 2025-01-10 东南大学 No供体化合物及其制备方法、药物组合物和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
US20250295677A1 (en) 2022-04-15 2025-09-25 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
TW202434258A (zh) 2023-02-27 2024-09-01 大陸商深圳艾欣達偉醫藥科技有限公司 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法
AU2024317010A1 (en) 2023-07-28 2026-02-26 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652579A (en) * 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
DE2229248C3 (de) 1971-07-30 1980-03-27 Gruppo Lepetit S.P.A., Mailand (Italien) 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung
US4921963A (en) * 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US4908356A (en) * 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
US5403932A (en) * 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5190929A (en) * 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
KR927003539A (ko) * 1990-01-26 1992-12-18 스즈끼 쯔네시 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제
US5233031A (en) * 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
CA2122036C (en) * 1991-10-23 2002-09-17 Gillian Anlezark Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
US5750782A (en) * 1992-11-27 1998-05-12 Cancer Research Campaign Technology Limited Nitroaniline derivatives and their use as anti-tumour agents
US5306727A (en) * 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
WO1994027954A1 (en) * 1993-05-25 1994-12-08 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
EP0648503B1 (en) * 1993-09-22 2000-07-26 Hoechst Aktiengesellschaft Pro-prodrugs, their production and use
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5659061A (en) 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9526391D0 (en) 1995-12-22 1996-02-21 Diversey Equipment Technologie Dispenser
US6218519B1 (en) * 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6251933B1 (en) * 1996-12-13 2001-06-26 The Cancer Research Campaign Technology Limited Seco precursors of cyclopropylindolines and their use as prodrugs
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
US6240925B1 (en) * 1999-03-23 2001-06-05 Cynosure, Inc. Photothermal vascular targeting with bioreductive agents
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
EP1185276B1 (en) * 1999-05-24 2003-12-10 Southern Research Institute Isophosphoramide mustard analogs and use thereof
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
US6903081B2 (en) * 2000-03-31 2005-06-07 Purdue Research Foundation Phosphoramidates and methods therefor
JP2002046334A (ja) 2000-08-04 2002-02-12 Riso Kagaku Corp 孔版印刷装置及び該装置の印刷ドラム
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6506739B1 (en) 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR20030067275A (ko) 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
JP4187096B2 (ja) 2003-01-15 2008-11-26 独立行政法人科学技術振興機構 ３次元フォトニック結晶製造方法
GB0306908D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
KR101226631B1 (ko) 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
MX2007006102A (es) 2004-11-22 2007-07-11 Threshold Pharmaceuticals Inc Agentes anti-cancer de union a tubulina y profarmacos de los mismos.
WO2008011588A2 (en) 2006-07-20 2008-01-24 Threshold Pharmaceuticals, Inc. Glycoconjugates of phosphoramidate alkylators for treatment of cancer
WO2008076826A1 (en) 2006-12-13 2008-06-26 Threshold Pharmaceuticals, Inc. Pyrophosphoramide alkylators
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2006521409A5 (https=)
CA2520000A1 (en) Compositions and methods for treating cancer
US9226932B2 (en) Phosphoramidate alkylator prodrugs
US6077862A (en) Virus and cancer treatments
CA2217952C (en) A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers
ME02121B (me) Kombinovana terapija sa parp inhibitorima
US6822001B2 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20080214576A1 (en) Topoisomerase Inhibitors and Prodrugs
WO2006015191A2 (en) Multicyclic lonidamine analogs
Ki et al. Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction
TH88192A (th) 5-เอริลไพริมิดีนเป็นสารต้านมะเร็ง